MDxHealth (MDXH) Registration Filing summary

Company overview and business model

• Commercial-stage precision diagnostics company focused on non-invasive, cost-effective urologic solutions, primarily for prostate cancer diagnosis and management.

• Core testing solutions include ExoDx, Confirm mdx, and Genomic Prostate Score (GPS), all providing personalized genomic insights.

• Over 7,000 physicians have ordered more than 500,000 tests; products are included in major U.S. prostate cancer guidelines and have Medicare coverage.

• Recent acquisition of Exosome Diagnostics, Inc. (ExoDx test) for up to $15 million, with $5 million in stock at closing and $2.5 million annually over four years.

• Revenue diversification efforts include additional tests such as Resolve mdx and ongoing development of new products.

Financial performance and metrics

• As of December 31, 2024, accumulated deficit was $369.5 million; net loss for 2024 was $38.1 million; net cash outflows from operations were $18.5 million.

• Confirm mdx and GPS tests accounted for 80% of 2024 revenue; Medicare represented 41% of 2024 revenue.

• Cash and cash equivalents as of December 31, 2025, were $29 million; total equity was negative $11.2 million; total loans and borrowings were $76.2 million.

• Outstanding deferred payments for acquisitions: $10 million for Exosome Diagnostics and up to $54.5 million for GPS business.

Use of proceeds and capital allocation

• Net proceeds from the offering will be used for general corporate and working capital purposes, including product development and commercialization expansion.

• Management retains significant discretion over allocation of proceeds; plans may change and will be updated in prospectus supplements.